

Erlina Burhan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11827567/publications.pdf>

Version: 2024-02-01

21
papers

1,626
citations

759233

12
h-index

794594

19
g-index

25
all docs

25
docs citations

25
times ranked

3297
citing authors

#	ARTICLE	IF	CITATIONS
1	Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19. <i>Journal of Clinical Medicine</i> , 2022, 11, 2961.	2.4	2
2	Expert review on global real-world vaccine effectiveness against SARS-CoV-2. <i>Expert Review of Vaccines</i> , 2022, 21, 1255-1268.	4.4	30
3	A living WHO guideline on drugs to prevent covid-19. <i>BMJ, The</i> , 2021, 372, n526.	6.0	73
4	Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 9, 100108.	2.9	75
5	Umbilical Cord Mesenchymal Stromal Cells as Critical COVID-19 Adjuvant Therapy: A Randomized Controlled Trial. <i>Stem Cells Translational Medicine</i> , 2021, 10, 1279-1287.	3.3	107
6	Integration of symptomatic, demographical and diet-related comorbidities data with SARS-CoV-2 antibody rapid diagnostic tests during epidemiological surveillance: a cross-sectional study in Jakarta, Indonesia. <i>BMJ Open</i> , 2021, 11, e047763.	1.9	2
7	Catastrophic costs due to tuberculosis worsen treatment outcomes: a prospective cohort study in Indonesia. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2020, 114, 666-673.	1.8	12
8	Evaluation and comparison of automated and manual ELISA for diagnosis of chronic pulmonary aspergillosis (CPA) in Indonesia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 98, 115124.	1.8	14
9	A living WHO guideline on drugs for covid-19. <i>BMJ, The</i> , 2020, 370, m3379.	6.0	664
10	Cost of seeking care for tuberculosis since the implementation of universal health coverage in Indonesia. <i>BMC Health Services Research</i> , 2020, 20, 502.	2.2	15
11	Effect of financial support on reducing the incidence of catastrophic costs among tuberculosis-affected households in Indonesia: eight simulated scenarios. <i>Infectious Diseases of Poverty</i> , 2019, 8, 10.	3.7	27
12	Pneumococcal pneumonia and invasive pneumococcal disease: immunopathogenesis and diagnosis. <i>Pneumologia</i> , 2019, 68, 8-14.	0.1	1
13	Adjunctive dexamethasone for the treatment of HIV-infected adults with tuberculous meningitis (ACT) Tj ETQq1 1 0.784314 rrgBT /Ov	1.8	14
14	The Effect of Several Different Decontaminant Solutions for Sputum in Inhibiting Contamination of Mycobacterium Tuberculosis Culture. <i>Advanced Science Letters</i> , 2018, 24, 6930-6933.	0.2	0
15	The path to impact of operational research on tuberculosis control policies and practices in Indonesia. <i>Global Health Action</i> , 2016, 9, 29866.	1.9	6
16	How do private general practitioners manage tuberculosis cases? A survey in eight cities in Indonesia. <i>BMC Research Notes</i> , 2015, 8, 564.	1.4	22
17	Supporting progress towards the post-2015 targets and regional tuberculosis elimination: a statement of intent from the third meeting of the Asian TB Experts Community. <i>European Respiratory Journal</i> , 2015, 45, 1760-1762.	6.7	2
18	Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. <i>European Respiratory Journal</i> , 2015, 46, 1563-1576.	6.7	475

#	ARTICLE	IF	CITATIONS
19	Reply to "Strategy To Limit Sampling of Antituberculosis Drugs Instead of Determining Concentrations at Two Hours Postingestion in Relation to Treatment Response". Antimicrobial Agents and Chemotherapy, 2014, 58, 629-630.	3.2	0
20	Isoniazid, Rifampin, and Pyrazinamide Plasma Concentrations in Relation to Treatment Response in Indonesian Pulmonary Tuberculosis Patients. Antimicrobial Agents and Chemotherapy, 2013, 57, 3614-3619.	3.2	81
21	Effectiveness and safety profile of mesenchymal stem cell secretome as a treatment for severe cases of COVID-19: a randomized controlled trial. F1000Research, 0, 11, 143.	1.6	2